| NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. | |
| | |
MedLine Citation:
|
PMID: 12527664 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate whether measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) can be used to differentiate patients with normal and reduced left ventricular ejection fraction (LVEF) in an unselected consecutive group of hospital inpatients. SETTING: City general hospital, Copenhagen, Denmark. PATIENTS AND DESIGN: During a 10 month period 2230 admissions to a city general hospital (80% of targeted patients) had an echocardiographic evaluation of left ventricular function, a comprehensive clinical evaluation, and blood analysis of N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 24 hours of admission. Exclusions resulted from lack of informed consent or failure to obtain the required evaluations before death or discharge from hospital. Echocardiography was unsatisfactory in 37 patients, so the final number studied was 2193. RESULTS: A raised NT-proBNP (>or= 357 pmol/l) identified patients with an LVEF of <or= 40% (n = 157) with a sensitivity of 73% and a specificity of 82%. The negative predictive value of having an NT-proBNP concentration below 357 pmol/l was 98%. Concentrations of NT-proBNP increased with increasing age and with decreasing LVEF (p < 0.05). A predicted concentration of NT-proBNP (corrected for age, sex, and serum creatinine) was determined for each patient. In patients with an NT-proBNP value less than predicted, the probability of having an LVEF of > 40% was more than 97%. This probability rapidly decreased to 70% as the measured NT-proBNP increased to 150% of the predicted value. CONCLUSIONS: A single measurement of NT-proBNP at the time of hospital admission provides important information about LVEF in unselected patients. |
| | |
Authors:
|
M Bay; V Kirk; J Parner; C Hassager; H Nielsen; K Krogsgaard; J Trawinski; S Boesgaard; J Aldershvile |
Related Documents
:
|
20550974 - Mortality of newly diagnosed heart failure treated with amiodarone a propensity-matched... 20009044 - Clinical effectiveness of implantable cardioverter-defibrillators among medicare benefi... 9104144 - Supporting hope in congestive heart failure patients. 20136614 - Current treatment of heart failure in the usa. 12666064 - Outcome of anca-associated renal vasculitis: a 5-year retrospective study. 23622424 - Patients readmitted to the intensive care unit: can they be prevented? |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Heart (British Cardiac Society) Volume: 89 ISSN: 1468-201X ISO Abbreviation: Heart Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-01-15 Completed Date: 2003-03-07 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 9602087 Medline TA: Heart Country: England |
Other Details:
|
Languages: eng Pagination: 150-4 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Amager Hospital, Copenhagen, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Aged, 80 and over Biological Markers / blood Cardiac Output, Low / diagnosis, physiopathology Echocardiography / methods Female Humans Male Middle Aged Natriuretic Peptide, Brain Nerve Tissue Proteins / blood* Peptide Fragments / blood* Sensitivity and Specificity Stroke Volume / physiology Ventricular Dysfunction, Left / diagnosis*, physiopathology |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Nerve Tissue Proteins; 0/Peptide Fragments; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessment of myocardial perfusion abnormalities by intravenous myocardial contrast echocardiography...
Next Document: Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: ...